Morning or night? study seeks best time for colitis drug
NCT ID NCT05213234
First seen Jan 11, 2026 · Last updated Jun 16, 2026 · Updated 25 times
Summary
This study looks at whether taking a common ulcerative colitis medication (5-ASA) in the morning versus the evening can better control hidden inflammation and improve gut health. About 32 adults with inactive ulcerative colitis but signs of low-level inflammation will take their once-daily pill at two different times for one month each. Researchers will measure inflammation, medication levels in the gut, and sleep patterns to find the most effective timing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rush University Medical Center
Chicago, Illinois, 60068, United States
-
The Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.